| RESEARCH ARTICLE |
|
| Year : 2015 | Volume
: 14
| Issue : 2 | Page : 33-37 |
|
|
Comparative effects of three iron chelation therapies on the quality of life of patients with homozygous transfusion-dependent beta-thalassemia
Jamal Q walii, Majid Naji Agha
Director of thalassemia center, Kirkuk, Iraq
Correspondence Address:
 Source of Support: None, Conflict of Interest: None
|
|
|
Background: Beta-thalassemia is a genetically inherited disorder characterized by reduced synthesis of the beta chain hemoglobin. Treatment consists of blood transfusion and chelating therapy in a form of paranteral deferoxamine (DFO) and oral deferasirox (DFX).
Aim of the study: To compare the quality of life, patient satisfactory adherence to the three different modalities of treatment.
Objectives: To compare three groups of patients receiving different modalities of treatment and the effect on their daily activities.
Patients and methods: A total of 270 patients (118)male and (152) female enrolled in the study, their age ranging from (10.5 year)-till (17 year), for the period from (May 2013—till May 2014), A special Questionnaire was arranged including three parts, First was on demographic data, the second part included Wallstons health locus of control scale and the third part included the patients satisfaction.
Results: The ratio of male to female were (1—1.3).The most common drug used was (DFX) (55.5%).Life style scale regarding ability to perform daily activity showed (90.6%) of patients on (DFX). About patient adherence to treatment (45.3%) of (DFX) group of patients.
Conclusion: It is concluded that optimal chelating therapy should be individualized for each patient to enhance their adherence and improve the quality of their life.
|
|
|
|
| [PDF]* |
|
 |
|
